publication venue for
- Abstract CT122: Randomized assessment of cisplatin dose interval for ototoxicity in the treatment of locally advanced squamous cell carcinoma of the head and neck undergoing curative concurrent chemoradiotherapy (RADIO) 2019
- Society for Clinical Trials Data Monitoring Committee initiative website: Closing the gap. 21:763-764. 2024
- Detecting irregularities in randomized controlled trials using machine learning.. 17407745241297947. 2024
- Pragmatic monitoring of emerging efficacy data in randomized controlled trials.. 17407745241290729. 2024
- A hybrid automated event adjudication system for clinical trials. 20:166-175. 2023
- Cognitive screening considerations for psychosocial clinical trials in HIV, aging, and cognition. 20:176-180. 2023
- A Bayesian adaptive design for clinical trials of rare efficacy outcomes with multiple definitions. 19:613-622. 2022
- Ethically designing research to inform multidimensional, rapidly evolving policy decisions: Lessons learned from the PROMISE HIV Perinatal Prevention Trial. 18:681-689. 2021
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. 17:491-500. 2020
- Bayesian methods for pilot studies. 17:414-419. 2020
- Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study. 17:202-211. 2020
- Access to clinical trial data—Commentary. 16:552-554. 2019
- Numbers can save lives: Janice Pogue (1962–2016). 13:464-465. 2016
- Randomized controlled trials in the West African Ebola virus outbreak. 13:10-12. 2016
- An interview with David Sackett, 2014–2015. 12:540-551. 2015
- Clinician trialist rounds: 28. When RCT participants are lost to follow-up. Part 1: Why even a few can matter. 12:537-539. 2015
- Clinician-trialist rounds: 25. Designing an evidence-based introductory graduate course in clinical trials. Part 2: Applying the evidence to your RCT course design. 12:91-93. 2015
- Clinician-trialist rounds: 24. Modernizing your introductory graduate course in clinical trials. Part 1: Commonsense meets evidence. 11:681-684. 2014
- Commentary on ‘Elm et al’. 11:473-475. 2014
- Data collection in cancer clinical trials: Too much of a good thing?. 10:624-632. 2013
- Lessons learned from a resident-led clinical trial in obstetrics. 10:612-616. 2013
- Central statistical monitoring: Detecting fraud in clinical trials. 10:225-235. 2013
- Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods. 10:54-62. 2013
- Clinician-trialist rounds: 12. When your grant gets turned down - part 2: resurrection. 9:660-663. 2012
- Clinician-trialist rounds: 11. When your grant gets turned down – part 1: remorse, anger, and reconciliation. 9:447-449. 2012
- Organizational- and employee-level recruitment into a worksite-based weight loss study. 9:215-225. 2012
- Author Response. 8:726-726. 2011
- What information should a sponsor of a randomized trial receive during its conduct?. 8:716-719. 2011
- Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials. 8:260-269. 2011
- Comments on ‘Sequential meta-analysis: an efficient decision-making tool’ by I van der Tweel and C Bollen. 7:752-753. 2010
- Damage to important clinical trials by over-regulation. 7:622-625. 2010
- Trends in the application of dynamic allocation methods in multi-arm cancer clinical trials. 7:227-234. 2010
- Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. 6:416-429. 2009
- Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. 6:239-251. 2009
- Optimal sample size determinations from an industry perspective based on the expected value of information. 5:587-594. 2008
- Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. 5:289-300. 2008
- Erratum. 5:283-283. 2008
- Randomized Trials in Vulnerable Populations. 5:61-69. 2008
- Sensible guidelines for the conduct of large randomized trials. 5:38-39. 2008
- Specific barriers to the conduct of randomized trials. 5:40-48. 2008
- Clinical decision making and the expected value of information. 4:279-285. 2007
- Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board. 4:218-234. 2007
- Non-surgical management of stress urinary incontinence: ambulatory treatments for leakage associated with stress (ATLAS) trial. 4:92-101. 2007
- Monitoring the randomized trials of the Women's Health Initiative the experience of the data and safety monitoring board. 4:218-234. 2007
- Independent design and conduct of clinical trials. 3:503-507. 2006